Clinical Report: Can Photobiomodulation Regulate Dry AMD?
Overview
The LIGHTSITE III trial demonstrated that photobiomodulation (PBM) significantly improves best-corrected visual acuity (BCVA) in patients with dry age-related macular degeneration (AMD) compared to sham treatment. The FDA has authorized the Valeda Light Delivery System for this indication, highlighting the potential of PBM in managing dry AMD.
Background
Dry age-related macular degeneration (AMD) is a leading cause of vision loss in older adults, characterized by gradual retinal degeneration. The introduction of photobiomodulation (PBM) as a treatment option represents a significant advancement, as it aims to enhance mitochondrial function and reduce inflammation in the retina. Understanding the efficacy and safety of PBM is crucial for integrating this therapy into clinical practice.
Data Highlights
| Study | BCVA Gain (ETDRS Letters) | New Geographic Atrophy (GA) |
|---|---|---|
| PBM Group (LIGHTSITE III) | 5.9 | 1 of 87 |
| Sham Group (LIGHTSITE III) | 1.0 | 5 of 50 |
Key Findings
- The LIGHTSITE III trial showed a mean BCVA gain of 5.9 letters in the PBM group at 24 months.
- New GA occurred in only 1 of 87 PBM-treated eyes compared to 5 of 50 in the sham group (P=.024).
- No significant change in subretinal pigment epithelial macular drusen volume was observed in the PBM group.
- The study reported a favorable safety profile for PBM treatment.
- Nearly half of the visual gains occurred within the first month, raising questions about the treatment's long-term efficacy.
Clinical Implications
Clinicians should consider PBM as a potential treatment for patients with dry AMD, particularly those with intermediate stages. Ongoing monitoring of visual acuity and potential side effects is essential, especially given the small absolute improvements observed.
Conclusion
The findings from the LIGHTSITE III trial support the use of PBM in improving visual outcomes for patients with dry AMD, although further research is needed to confirm long-term benefits and safety.
References
- Ophthalmic Professional, July 2025 -- Photobiomodulation for Dry AMD
- Retinal Physician, March 2025 -- Photobiomodulation Therapy Delays Dry AMD Progression
- Ophthalmic Professional, July 2025 -- Photobiomodulation for Dry AMD
- Ophthalmology, April 2025 -- Clinical Guidelines for Dry AMD
- PubMed, LIGHTSITE III Trial -- Efficacy and Safety of PBM
- Ophthalmology and Therapy -- Systematic Review on PBM
- Ophthalmology | Vol 132, Issue 4, Pages A1-A20, P1-P344, e1-e78, 375-506 (April 2025) | ScienceDirect.com by Elsevier
- LIGHTSITE III: 13-Month Efficacy and Safety Evaluation of Multiwavelength Photobiomodulation in Nonexudative (Dry) Age-Related Macular Degeneration Using the Lumithera Valeda Light Delivery System - PubMed
- Is Multiwavelength Photobiomodulation Effective and Safe for Age-Related Macular Degeneration? A Systematic Review and Meta-Analysis | Ophthalmology and Therapy | Springer Nature Link
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
